334 related articles for article (PubMed ID: 29671012)
1. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
2. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
3. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
5. [Peculiarity of infantile cystinosis in Tunisian children].
Jellouli M; Ben Turkia H; Abidi K; Hammi Y; Gargah T
Pan Afr Med J; 2015; 22():348. PubMed ID: 26985266
[TBL] [Abstract][Full Text] [Related]
6. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
7. [Cystinosis in adults: A systemic disease].
Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
9. Extrarenal complications of cystinosis.
Topaloglu R
Pediatr Nephrol; 2024 Aug; 39(8):2283-2292. PubMed ID: 38127152
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
11. Nephropathic cystinosis: an update on genetic conditioning.
Topaloglu R
Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
[TBL] [Abstract][Full Text] [Related]
13. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
[No Abstract] [Full Text] [Related]
15. [Improved prognosis of cystinosis achieved by treatment with cysteamine and by kidney transplantation].
Oczachowska-Kulik AE; Lund AM; Skovby F; Pedersen EB
Ugeskr Laeger; 2011 Aug; 173(33):1958-62. PubMed ID: 21849135
[TBL] [Abstract][Full Text] [Related]
16. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
[TBL] [Abstract][Full Text] [Related]
17. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
19. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
[TBL] [Abstract][Full Text] [Related]
20. Quiz page. Fanconi syndrome caused by cystinosis, intermediate type.
Ram R; Swarnalatha G; Reddy PN; Prasad N; Dakshinamurty KV
Am J Kidney Dis; 2009 Dec; 54(6):xxxviii-xxxix. PubMed ID: 19932873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
